Protocol | NRG BN011 |
---|---|
Cancer Type: | Methylated MGMT Promoter Glioblastoma |
Fast Facts |
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071401 |
---|---|
Cancer Type: | MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS |
Fast Facts |
PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS
Protocol | NRG BN003 |
---|---|
Cancer Type: | MENINGIOMA |
Fast Facts |
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071701 |
---|---|
Cancer Type: | Brain metastases |
Fast Facts |
Genomically-Guided Treatment Trial in Brain Metastases
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2212 |
---|---|
Cancer Type: | Breast |
Fast Facts |
SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY |
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A011801 |
---|---|
Cancer Type: | HER2 positive Breast Cancer |
Fast Facts |
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Protocol | Alliance A012103 |
---|---|
Cancer Type: | Breast- Post-Neoadjuvant |
Fast Facts |
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | CCTG MA.39 Adjuvant |
---|---|
Cancer Type: | LOW RISK NODE POSITIVE BREAST CANCER |
Fast Facts |
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Protocol | NRG BR007 |
---|---|
Cancer Type: | Stage 1, Hormone Sensitive Her2 negative |
Fast Facts |
Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation
Protocol | NRG BR009 |
---|---|
Cancer Type: | Breast |
Fast Facts |
Protocol NRG-BR009, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) (NCT05879926)
Protocol | NRG BR008 |
---|---|
Cancer Type: | Breast |
Fast Facts |
NRG-BR008, "A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer” (HERO)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2007 |
---|---|
Cancer Type: | HER2-Negative Breast Cancer |
Fast Facts |
A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases
Protocol | EAY191 - N2 |
---|---|
Cancer Type: | Rare Cancer |
Fast Facts |
PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2010 |
---|---|
Cancer Type: | Breast |
Fast Facts |
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)
Protocol | WF 2202 |
---|---|
Cancer Type: | Breast |
Fast Facts |
WF-2202, Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial
Protocol | EAQ221CD |
---|---|
Cancer Type: | Breast |
Fast Facts |
EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)
Protocol | SWOG S1703 |
---|---|
Cancer Type: | METASTATIC BREAST CANCER |
Fast Facts |
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Protocol | Alliance A191901 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA1151 (TMIST) |
---|---|
Cancer Type: | Screening |
Fast Facts |
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAQ221CD |
---|---|
Cancer Type: | Breast |
Fast Facts |
EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAQ222CD |
---|---|
Cancer Type: | CCDR - multsite |
Fast Facts |
EAQ222CD: “Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients”
Protocol | SWOG S1912CD |
---|---|
Cancer Type: | CCDR |
Fast Facts |
A RANDOMIZED TRIAL ADDRESSING CANCER-RELATED FINANCIAL HARDSHIP THROUGH
DELIVERY OF A PROACTIVE FINANCIAL NAVIGATION INTERVENTION (CREDIT)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Protocol | Alliance A212102 |
---|---|
Cancer Type: | Early Detection Blood Tests |
Fast Facts |
Blinded Reference Set for Multicancer Early Detection Blood Tests
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1703 |
---|---|
Cancer Type: | METASTATIC BREAST CANCER |
Fast Facts |
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Protocol | Alliance A191901 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Protocol | WF 2202 |
---|---|
Cancer Type: | Breast |
Fast Facts |
WF-2202, Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 1806 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A211901 |
---|---|
Cancer Type: | Rural Cancer Survivors |
Fast Facts |
REACHING RURAL CANCER SURVIVORS WHO SMOKE USING TEXT-BASED CESSATION INTERVENTIONS
Protocol | URCC 21038 |
---|---|
Cancer Type: | Cancer Survivors |
Fast Facts |
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
Protocol | SWOG S2205 |
---|---|
Cancer Type: | peripheral neuropathy |
Fast Facts |
S2205, ICE COMPRESS: RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY
Protocol | URCC 22063 (LOTUS) |
---|---|
Cancer Type: | Observational |
Fast Facts |
Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
Protocol | URCC 19075 |
---|---|
Cancer Type: | multi-site |
Fast Facts |
URCC-19075 “Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)”
Protocol | URCC 18007 |
---|---|
Cancer Type: | Cancer-Related Fatigue |
Fast Facts |
Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA1151 (TMIST) |
---|---|
Cancer Type: | Screening |
Fast Facts |
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Protocol | DCP-001 |
---|---|
Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Protocol | NRG CC005 FORTE |
---|---|
Cancer Type: | Colonoscopy |
Fast Facts |
FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A021804 |
---|---|
Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2012 |
---|---|
Cancer Type: | Multi-site |
Fast Facts |
S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A092001 |
---|---|
Cancer Type: | RARE |
PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GI008 |
---|---|
Cancer Type: | Colon Adjuvant |
Fast Facts |
COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2001 |
---|---|
Cancer Type: | Metastatic Pancreatic |
Fast Facts |
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.
Protocol | Alliance A021806 |
---|---|
Cancer Type: | RESECTABLE PANCREATIC CANCER |
Fast Facts |
A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Protocol | Alliance A022106 |
---|---|
Cancer Type: | Pancreatic |
Fast Facts |
A022106: “Phase II/III second-line NABPLAGEM vs. nab-paclitaxel/gemcitabine in BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1922 |
---|---|
Cancer Type: | Small bowel Adenocarcinoma |
Fast Facts |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2197 |
---|---|
Cancer Type: | Incidental Gallbladder Cancer |
Fast Facts |
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial
Protocol | EAY191 - A6 |
---|---|
Cancer Type: | Rare Cancer |
A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2222 |
---|---|
Cancer Type: | Colorectal |
Fast Facts |
A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial.
Protocol | CCTG CO32 |
---|---|
Cancer Type: | Early Rectal Cancer |
Fast Facts |
The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus ChemoRadioTherapy for Early Rectal Cancer
Protocol | NRG GI004 |
---|---|
Cancer Type: | Colorectal Cancer |
Fast Facts |
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2212 |
---|---|
Cancer Type: | Gastric and GEJ |
Fast Facts |
EA2212, “A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer”
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 1806 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
Please check out the rare protocol list to locate other studies within this disease site.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1802 |
---|---|
Cancer Type: | Metastatic Prostate Cancer |
Fast Facts |
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Protocol | EA8171 |
---|---|
Cancer Type: | Prostate Cancer |
Fast Facts |
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
Protocol | NRG GU009 |
---|---|
Cancer Type: | HIGH RISK PROSTATE CANCER |
Fast Facts |
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
Protocol | NRG GU010 |
---|---|
Cancer Type: | Prostate Cancer |
Fast Facts |
NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Protocol | NRG GU011 |
---|---|
Cancer Type: | Prostate |
Fast Facts |
NRG-GU011, A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)
Protocol | NRG GU013 |
---|---|
Cancer Type: | Prostate |
Fast Facts |
NRG-GU013, The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2200 |
---|---|
Cancer Type: | Renal Cell |
Fast Facts |
SWOG - S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).”
Protocol | SWOG S1931 |
---|---|
Cancer Type: | METASTATIC RENAL CELL CARCINOMA |
Fast Facts |
PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A031803 |
---|---|
Cancer Type: | BCG-Unresponsive Non Muscle Invasive Bladder |
Fast Facts |
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Protocol | SWOG S1937 |
---|---|
Cancer Type: | Metastatic Urothelial Carcinoma |
Fast Facts |
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Please check out the rare protocol list to locate other studies within this disease site.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG CC008 |
---|---|
Cancer Type: | Ovarian Cancer Among BRCA1 Carriers |
Fast Facts |
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Protocol | NRG GY019 |
---|---|
Cancer Type: | Carcinoma of the Ovary or Peritoneum |
Fast Facts |
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Protocol | EAY191 - N4 |
---|---|
Cancer Type: | Rare Cancer |
A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GY026 |
---|---|
Cancer Type: | Endometrial serous carcinoma or carcinosarcoma |
Fast Facts |
A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GY024 |
---|---|
Cancer Type: | Vulvar Cancer |
Fast Facts |
Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III), a prospective phase II treatment trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA3132 |
---|---|
Cancer Type: | Head and Neck |
Fast Facts |
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Protocol | RTOG 1216 |
---|---|
Cancer Type: | Pathologic High-Risk Squamous Cell Cancer |
Fast Facts |
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG HN010 |
---|---|
Cancer Type: | RARE |
A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAY191 - N2 |
---|---|
Cancer Type: | Rare Cancer |
Fast Facts |
PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A021804 |
---|---|
Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1922 |
---|---|
Cancer Type: | Small bowel Adenocarcinoma |
Fast Facts |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Protocol | Alliance A092001 |
---|---|
Cancer Type: | RARE |
PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA
Protocol | EAY191 - A6 |
---|---|
Cancer Type: | Rare Cancer |
A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS
Please check out the rare protocol list to locate other studies within this disease site.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG HN010 |
---|---|
Cancer Type: | RARE |
A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAY191 - N4 |
---|---|
Cancer Type: | Rare Cancer |
A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS
Protocol | EAY191 - S3 |
---|---|
Cancer Type: | Rare Cancer |
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A041501 |
---|---|
Cancer Type: | NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
Fast Facts |
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1925 |
---|---|
Cancer Type: | CLL/SLL |
Fast Facts |
RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A081801 |
---|---|
Cancer Type: | resected NSCLC |
Fast Facts |
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
Protocol | EA5162 |
---|---|
Cancer Type: | Advanced NSCLC |
Fast Facts |
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
Protocol | SWOG S1900E |
---|---|
Cancer Type: | NS NSCLC |
Fast Facts |
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)
Protocol | SWOG S2302 |
---|---|
Cancer Type: | Lung |
Fast Facts |
Non-Chemotherapy Treatment (ramucirumab plus pembrolizumab) or Usual Care forAdvanced Non-Small Cell Lung Cancer Following Immunotherapy
Protocol | Alliance A082002 |
---|---|
Cancer Type: | Non-Small Cell Lung Cancer |
Fast Facts |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Protocol | NRG LU008 |
---|---|
Cancer Type: | Lung Cancer |
Fast Facts |
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1827 |
---|---|
Cancer Type: | Small Cell Lung |
Fast Facts |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Protocol | NRG LU007 |
---|---|
Cancer Type: | ES-SCLC |
Fast Facts |
RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A151216 |
---|---|
Cancer Type: | Non-Small Cell Lung |
Fast Facts |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Sub-Studies to ALCHEMIST: E4512 and EA5142
Protocol | LUNG MAP |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2114 |
---|---|
Cancer Type: | Lymphoma |
Fast Facts |
A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1925 |
---|---|
Cancer Type: | CLL/SLL |
Fast Facts |
RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AHOD2131 |
---|---|
Cancer Type: | Classic Hodgkin Lymphoma |
Fast Facts |
COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Patients must be 5 to 60 years of age at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAQ211 |
---|---|
Cancer Type: | Lymphoma |
Fast Facts |
EAQ211: Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | URCC 19075 |
---|---|
Cancer Type: | multi-site |
Fast Facts |
URCC-19075 “Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)”
Protocol | URCC 18007 |
---|---|
Cancer Type: | Cancer-Related Fatigue |
Fast Facts |
Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | TAPUR |
---|---|
Cancer Type: | Multisite |
Fast Facts |
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Protocol | Alliance A071701 |
---|---|
Cancer Type: | Brain metastases |
Fast Facts |
Genomically-Guided Treatment Trial in Brain Metastases
Protocol | Alliance EAY 191-A3 |
---|---|
Cancer Type: | Rare Cancer |
Fast Facts |
A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers
Protocol | EAY191 - S3 |
---|---|
Cancer Type: | Rare Cancer |
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors
Protocol | EAY191 - A3 |
---|---|
Cancer Type: | Rare Cancer |
Fast Facts |
A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | 10323 Moonshot |
---|---|
Cancer Type: | Biospecimen |
Fast Facts |
Cancer Moonshot Biobank Research Protocol
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAQ222CD |
---|---|
Cancer Type: | CCDR - multsite |
Fast Facts |
EAQ222CD: “Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients”
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAY191 |
---|---|
Cancer Type: | Multisite |
Fast Facts |
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Protocol | DCP-001 |
---|---|
Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAA181 |
---|---|
Cancer Type: | Newly diagnosed Multiple Myeloma |
Fast Facts |
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2209 |
---|---|
Cancer Type: | Mulitple Myloma |
Fast Facts |
S2209 A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-drug Induction Regimens Followed by Double- or Single-Agent Maintenance
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAA173 |
---|---|
Cancer Type: | Smoldering Myeloma |
Fast Facts |
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1803 |
---|---|
Cancer Type: | Multiple Myeloma |
Fast Facts |
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AOST2031 |
---|---|
Cancer Type: | Osteosarcoma |
Fast Facts |
COG AOST2031
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Patients must be < 50 years at the time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ECOG EA6141 |
---|---|
Cancer Type: | Melanoma-unresectable |
Fast Facts |
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Protocol | EA6192 |
---|---|
Cancer Type: | Advanced Melanoma |
Fast Facts |
A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Protocol | SWOG S2015 |
---|---|
Cancer Type: | primary cutaneous melanoma |
Fast Facts |
Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
Protocol | Alliance A091903 |
---|---|
Cancer Type: | RESECTED MUCOSAL MELANOMA |
Fast Facts |
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.